|
|
Post by me on Jan 21, 2016 9:04:04 GMT -5
|
|
|
|
Post by harryx1 on Jan 21, 2016 9:09:13 GMT -5
It will be interesting to find out who is behind Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Great News!
|
|
|
|
Post by bearcatmax on Jan 21, 2016 9:09:46 GMT -5
I like that : Receptor being responsible for all development costs.
|
|
amuninni
Newbie
Posts: 22 
Sentiment: Long
|
Post by amuninni on Jan 21, 2016 9:10:22 GMT -5
finally some good news .... go MNKD
|
|
|
|
Post by therealisaching on Jan 21, 2016 9:10:45 GMT -5
No upfront money. That is disappointing. Hope we hear soon on what it takes to achieve an initial milestone. |
|
|
|
Post by trondisc on Jan 21, 2016 9:11:34 GMT -5
Absolute MEH. From a technical perspective this keeps MannKind over $1 PPS probably with no climb. The moment another large cap (ala Sanofi) Corporation shows interest it's off to the races.
|
|
|
|
Post by mindovermatter on Jan 21, 2016 9:14:02 GMT -5
I am not so sure the market is going to be satisfied when it realizes there is no up front money and not much is known about Receptor Life. Its website is just one page with a notification button. That's it. Talk about transparency. Receptor life has no transparency. Hopefully Matt can elaborate a bit more who this company is. Maybe it has Gates foundation funding but that's a guess.
|
|
|
|
Post by matt on Jan 21, 2016 9:14:15 GMT -5
Hard to comment on a deal with a "newly formed entity" when that entity is responsible for all development costs and the compensation is on milestones and royalties. It would be nice to know if this entity has the financing and capability to execute on their part of the deal or whether this agreement is largely illusory. This is not the kind of company venture capital likes to invest in, so it will be interesting to see where their money comes from. In pharma development, always follow the money!
Since the partner is not public information will be scarce. There is a profile for a Canadian company by the same name with two drugs, one a high-dose Vitamin D and the other a drug delivery technology, but the link to their homepage is dead so it is impossible to tell if this is the same company or not.
|
|
|
|
Post by mindovermatter on Jan 21, 2016 9:15:45 GMT -5
Absolute MEH. From a technical perspective this keeps MannKind over $1 PPS probably with no climb. The moment another large cap (ala Sanofi) Corporation shows interest it's off to the races. don't be so sure this news is going take MNKD over $1. Receptor life is a start up and I can't find squat about the company. |
|
|
|
Post by suebeeee1 on Jan 21, 2016 9:15:46 GMT -5
"Multiple inhaled therapeutic projects". Does not mention any "upfront" payments only potential milestone payments. And a very low royalty. I hope they didn't just transfer the bulk of potential for technosphere to a small new startup.
|
|
|
|
Post by mindovermatter on Jan 21, 2016 9:20:13 GMT -5
"Multiple inhaled therapeutic projects". Does not mention any "upfront" payments only potential milestone payments. And a very low royalty. I hope they didn't just transfer the bulk of potential for technosphere to a small new startup. Maybe it's a secret side project spun off from Sanofi! LOL One thing for sure is that it looks like we are back to silence from Mannkind with this "deal." |
|
|
|
Post by therealisaching on Jan 21, 2016 9:22:48 GMT -5
Website was created 11 days ago.
Domain Name: RECEPTORLIFE.COM
Registrar: ENOM, INC.
Sponsoring Registrar IANA ID: 48
Whois Server: whois.enom.com
Referral URL: www.enom.com
Name Server: DNS1.REGISTRAR-SERVERS.COM
Name Server: DNS2.REGISTRAR-SERVERS.COM
Name Server: DNS3.REGISTRAR-SERVERS.COM
Name Server: DNS4.REGISTRAR-SERVERS.COM
Name Server: DNS5.REGISTRAR-SERVERS.COM
Status: clientTransferProhibited www.icann.org/epp#clientTransferProhibited
Updated Date: 10-jan-2016
Creation Date: 10-jan-2016
Expiration Date: 10-jan-2017
|
|
|
|
Post by bill on Jan 21, 2016 9:23:17 GMT -5
I expect that Matt will be providing additional information today or tomorrow about the obvious questions...in the interests of more transparency  mindovermatter - Betting time? |
|
|
|
Post by mnholdem on Jan 21, 2016 9:24:41 GMT -5
Announcement of NDA submittals to the FDA will generate more buzz. Hopefully, RLS will get right on that. 
BTW, there are lots of nano-technology biotech development companies in Seattle. It may be strategically smart to do an end-around the mainstream pharmaceutical industry that may view MannKind's disruptive technology as a threat. |
|
|
|
Post by dictatorsaurus on Jan 21, 2016 9:26:25 GMT -5
Curious to know who is behind receptor. Website create recently. I don't think MNKD would sign unless there's strong backing.
|
|
